Atlantic Pharmaceuticals Elects Robert A. Fildes, Ph.D., As Chairman of the Board of Directors.RALEIGH, N.C--(BUSINESS WIRE)--June 16, 1998--Atlantic Pharmaceuticals, Inc. (Nasdaq SmallCap: ATLC ATLC Arbitrary Transmission Line Calculator ATLC Atomic Trades and Labor Council ATLC Air Transport Label Catalog ATLC Advanced Technology Licensing Company ) announced today that its board of directors has elected Robert A. Fildes, Ph.D., as chairman of the board of directors, effective immediately. Widely experienced as a senior executive in the biotechnology sector, Dr. Fildes was appointed as a member of the Company's board of directors on Oct. 24, 1997. "Atlantic Pharmaceuticals has benefited greatly from Dr. Fildes' counsel since he joined as a director last year," stated J. D. Lindjord, president and chief executive officer of Atlantic Pharmaceuticals. "His appointment as chairman of the board will give us an even greater opportunity to benefit from his seasoned perspective." Dr. Fildes was previously chairman and chief executive officer of Scotgen Biopharmaceuticals, Inc., president and chief executive officer of Cetus Corporation, and president of Biogen Inc. Earlier, he was associated with Bristol Myers Corporation, first as vice president of development and then as vice president of operations for the industrial division. Prior to that, he was head of fermentation research and development at Glaxo Welcome PLC, a British pharmaceutical company. Dr. Fildes is currently a member of the boards of directors at SB 2, Inc., Cytovax Biotechnologies, Inc., Carrington Laboratories, Inc., and La Jolla La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and Pharmaceuticals Company. He previously served as a director at Cascade Oncogenics, Inc., TSI TSI Total Solar Irradiance (sum solar light in energy per unit of time) TSI Trading Standards Institute (UK) TSI Transportation Safety Institute (US DOT) , Inc., Viagene, Inc., and Jenner Technologies, Inc. In addition, he is a founder and past board member of the Industrial Biotechnology The references in this article would be clearer with a different and/or consistent style of citation, footnoting or external linking. Industrial biotechnology (known mainly in Europe as white biotechnology Association and was formerly a member of the Haas School of Business advisory board at the University of California, Berkeley The University of California, Berkeley is a public research university located in Berkeley, California, United States. Commonly referred to as UC Berkeley, Berkeley and Cal , a board member of the Association of Biotechnology Companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. and a consultant to the U.S. Office of Technology Assessment. Dr. Fildes was graduated with a B.Sc. in chemistry and human physiology Human physiology is the science of the mechanical, physical, and biochemical functions of humans in good health, their organs, and the cells of which they are composed. The principal level of focus of physiology is at the level of organs and systems. from the University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies , where he also received a D.C.C. in microbiology and a Ph.D. in biochemical genetics. Based in Raleigh, NC, Atlantic Pharmaceuticals is a biopharmaceutical company developing pharmaceutical and biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. products for a variety of therapeutic areas. The Company's strategy, which differentiates its approach from many biotechnology firms, is to develop a diverse portfolio of promising and independent product candidates licensed from a variety of sources. Currently, Atlantic is developing novel, proprietary technologies in cataract removal, antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). gene therapy, prevention of restenosis following coronary angioplasty, and anti-inflammatory/analgesic drugs. This press release contains certain forward-looking statements that relate to future business, scientific and financial performance. Such statements can only be predictions and are subject to a number of factors and uncertainties, which may cause the actual events or future results to differ from those discussed herein. Such factors include those risks described in the Company's most recent reports on Forms 10-QSB and 10-KSB previously filed with the Securities and Exchange Commission. The Company assumes no obligation to update the information in this release. For more information on Atlantic Pharmaceuticals' technologies, visit the Company's homepage at http://www.atlan.com. Atlantic's press releases are available through BusinessWire's web site at http://www.businesswire.com. The releases also are available at no charge through BusinessWire's fax-on-demand service at 888-286-8109.
CONTACT: Media: Investors:
Mary Ann Dunnell Dian Griesel
(212) 484-7797 (212) 664-8489
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion